Biomarkers and novel agents in esophago-gastric cancer: are we making progress?

Asa Dahle-Smith; Russell D. Petty

doi:10.1586/14737140.2015.1071669

Biomarkers and novel agents in esophago-gastric cancer: are we making progress?

Asa Dahle-Smith, Russell D. Petty (Lead / Corresponding author)

Research output: Contribution to journal › Article › peer-review

6 Citations (Scopus)

Abstract

Esophago-gastric cancer (EGC) provides a formidable healthcare challenge. Conventional chemotherapy provides modest survival benefit in patients with advanced disease especially in the second-line setting. The recent paradigm shift in the oncology community towards targeting growth factor pathways and the immune system using novel targeted agents has now demonstrated clinical utility in EGC, but recent trial results have highlighted the complexity of disease pathogenesis and significant challenges remain. Here, we describe the current role of targeted therapies in EGC, and their corresponding biomarkers. We aim to provide a comprehensive review of the current climate of novel agents and their biomarkers in advanced EGC.

Original language	English
Pages (from-to)	1103-1119
Number of pages	17
Journal	Expert Review of Anticancer Therapy
Volume	15
Issue number	9
DOIs	https://doi.org/10.1586/14737140.2015.1071669
Publication status	Published - 2015

Keywords

Biomarkers
Esophageal cancer
Gastric cancer
Targeted agents
Translational medicine

ASJC Scopus subject areas

Pharmacology (medical)
Oncology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1586/14737140.2015.1071669

http://www.tandfonline.com/doi/full/10.1586/14737140.2015.1071669#.VgFyAH2gSSo

Cite this

@article{5febefd474864d06abec716c80e1a610,

title = "Biomarkers and novel agents in esophago-gastric cancer: are we making progress?",

abstract = "Esophago-gastric cancer (EGC) provides a formidable healthcare challenge. Conventional chemotherapy provides modest survival benefit in patients with advanced disease especially in the second-line setting. The recent paradigm shift in the oncology community towards targeting growth factor pathways and the immune system using novel targeted agents has now demonstrated clinical utility in EGC, but recent trial results have highlighted the complexity of disease pathogenesis and significant challenges remain. Here, we describe the current role of targeted therapies in EGC, and their corresponding biomarkers. We aim to provide a comprehensive review of the current climate of novel agents and their biomarkers in advanced EGC.",

keywords = "Biomarkers, Esophageal cancer, Gastric cancer, Targeted agents, Translational medicine",

author = "Asa Dahle-Smith and Petty, {Russell D.}",

year = "2015",

doi = "10.1586/14737140.2015.1071669",

language = "English",

volume = "15",

pages = "1103--1119",

journal = "Expert Review of Anticancer Therapy",

issn = "1473-7140",

publisher = "Taylor & Francis",

number = "9",

}

TY - JOUR

T1 - Biomarkers and novel agents in esophago-gastric cancer

T2 - are we making progress?

AU - Dahle-Smith, Asa

AU - Petty, Russell D.

PY - 2015

Y1 - 2015

N2 - Esophago-gastric cancer (EGC) provides a formidable healthcare challenge. Conventional chemotherapy provides modest survival benefit in patients with advanced disease especially in the second-line setting. The recent paradigm shift in the oncology community towards targeting growth factor pathways and the immune system using novel targeted agents has now demonstrated clinical utility in EGC, but recent trial results have highlighted the complexity of disease pathogenesis and significant challenges remain. Here, we describe the current role of targeted therapies in EGC, and their corresponding biomarkers. We aim to provide a comprehensive review of the current climate of novel agents and their biomarkers in advanced EGC.

AB - Esophago-gastric cancer (EGC) provides a formidable healthcare challenge. Conventional chemotherapy provides modest survival benefit in patients with advanced disease especially in the second-line setting. The recent paradigm shift in the oncology community towards targeting growth factor pathways and the immune system using novel targeted agents has now demonstrated clinical utility in EGC, but recent trial results have highlighted the complexity of disease pathogenesis and significant challenges remain. Here, we describe the current role of targeted therapies in EGC, and their corresponding biomarkers. We aim to provide a comprehensive review of the current climate of novel agents and their biomarkers in advanced EGC.

KW - Biomarkers

KW - Esophageal cancer

KW - Gastric cancer

KW - Targeted agents

KW - Translational medicine

UR - http://www.scopus.com/inward/record.url?scp=84940607603&partnerID=8YFLogxK

U2 - 10.1586/14737140.2015.1071669

DO - 10.1586/14737140.2015.1071669

M3 - Article

C2 - 26313419

AN - SCOPUS:84940607603

SN - 1473-7140

VL - 15

SP - 1103

EP - 1119

JO - Expert Review of Anticancer Therapy

JF - Expert Review of Anticancer Therapy

IS - 9

ER -

Biomarkers and novel agents in esophago-gastric cancer: are we making progress?

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this